Search results: (10000)
News Safety and Tolerance of Metamizole in Postoperative Analgesia in Children
Due to the potential serious side effects of metamizole, the use of this drug in children is often a topic of discussion. Therefore, a prospective multicenter observational non-interventional post-marketing safety study aimed to evaluate the safety of using metamizole in children, with an emphasis on hemodynamic, anaphylactic, or respiratory reactions and agranulocytosis.
News Iron Deficiency and Administration of Ferric Carboxymaltose in Patients with Heart Failure
Iron deficiency is very common in patients with heart failure and is associated with exercise intolerance, reduced quality of life, increased mortality, and higher risk of hospitalization, regardless of the presence of anemia. Clinical studies have previously demonstrated the positive effect of intravenous administration of ferric carboxymaltose (FCM) in patients with chronic heart failure with reduced ejection fraction of the left ventricle. The AFFIRM-AHF study investigated the effect of FCM administration initiated shortly before discharge from hospitalization for acute heart failure.
News CASE STUDY: Rocker who can enjoy life again thanks to DM2 compensation p.o. semaglutide and better lifestyle
Diabetologist MUDr. Lucie Radovnická from Masaryk Hospital in Ústí nad Labem illustrates the case of her patient − a sympathetic rocker who enjoys life including concerts, beer, and good food − demonstrating how modern antidiabetic treatment with oral semaglutide in combination with thorough lifestyle re-education can achieve very good diabetes compensation and overall health improvement. One of the many benefits of this modality was the possibility to discontinue sulfonylurea derivative medication, which previously caused severe hypoglycemia.
News Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for chronic lymphocytic leukemia (CLL) and are now an integral part of treatment regimens, including the 1st line. Individual therapeutic approaches and strategies based on them have their advantages and disadvantages as well as their target patient group, but the concept of time-limited treatment is increasingly gaining ground. Therapy today is significantly individualized, and its optimal choice is based on the assessment of various circumstances on the patient’s part and their disease.
News Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer
In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the course of the disease, causing so-called skeletal-related events (SREs). These events cause pain, increase morbidity, and reduce quality of life and mobility in patients. Antiresorptive agents, such as the bisphosphonate zoledronic acid or the osteoclast maturation and differentiation inhibitor denosumab, are used to prevent the occurrence of SREs. An exploratory analysis compared the effect of administering denosumab and zoledronic acid on the survival of patients with metastatic disease.
News Efficacy and Safety of an Activated FXII Inhibitor in Preventing HAE Attacks
Hereditary angioedema (HAE) is a rare, potentially life-threatening inherited disorder characterized by dysregulation of the kallikrein-kinin system. This results in excessive production of bradykinin, which is responsible for soft tissue edema. Garadacimab, a human antibody inhibiting activated factor XII, is utilized in the prevention of these attacks. Its efficacy and safety were verified in a phase III clinical trial.
News Adherence to Treatment of Multiple Sclerosis: How to Enhance It and What Interesting Insights Emerged from Current Research?
Therapeutic options for patients with multiple sclerosis (MS) utilizing disease-modifying drugs (DMDs) have continued to expand in recent years. However, achieving their full benefit is critically dependent on adherence to treatment. Nonadherence is demonstrably linked to an increased risk of relapses, faster progression of disability, higher treatment costs, and higher mortality. We present a summary of factors affecting adherence to treatment in MS patients, including the influence of the chosen therapy from a 2022 review and subsequent studies.
News EULAR 2023: How does tofacitinib affect cardiovascular risk in rheumatoid arthritis?
At this year's European League Against Rheumatism (EULAR) congress, held at the turn of May and June in Milan, Italy, a study was presented that examined the impact of tofacitinib use on cardiovascular (CV) risk in patients with active rheumatoid arthritis (RA).
News Patient with Moderate Hemophilia A and Development of FVIII Inhibitor in Old Age and Atrial Fibrillation − Interactive Case Study
MUDr. Petr Smejkal, Ph.D., from the Department of Clinical Hematology, FN Brno, has prepared a case study for you of a patient born in 1941, diagnosed with hemophilia A at around 10 years of age. In 2013, he underwent surgery for right carotid stenosis with pdFVIII substitution and was started on acetylsalicylic acid.
Two weeks after discharge, subcutaneous and muscle bleeding was recognized, leading to the development of an FVIII inhibitor (high responder) with FVIII levels < 1%. Severe muscle bleeds continued approximately once every 2 months. Prophylactic treatments progressively included aPCC, pdFVIII, and emicizumab.
The patient also presents with cardiovascular comorbidities: atrial fibrillation (AF) accompanied by its dilatation, diastolic heart failure, and hypertension. In 2021, he also contracted COVID-19, requiring hospitalization.
News The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
We summarize the results of a clinical study on the effect of probiotics containing Limosilactobacillus reuteri on the improvement of gingivitis in patients with diabetes. It has been proven that the supplementary administration of L. reuteri statistically significantly improves gum health and helps to suppress gingival inflammation.
News How do patients perceive the treatment of ITP with romiplostim?
Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
News ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in Lenzerheide, Switzerland, published late last year in the British Journal of Haematology, discusses the potential of early treatment of immune thrombocytopenia with thrombopoietin receptor agonists (TPO-RA) in achieving a disease remission sustainable without further therapy.
News Less Ventricular Arrhythmias and ICD Shocks After Introduction of Sacubitril/Valsartan
Is the decrease in the incidence of sudden cardiac death among patients using sacubitril/valsartan due to a lower risk of ventricular arrhythmias? And does it have anything to do with reverse left ventricular remodeling? A newly published study utilizing data from telemonitoring of patients with implanted devices focused on this.
News Severe Polytrauma in a Man with von Willebrand Disease − Case Report
The authors of a recently published case report present a case of multiple trauma (including brain injury) in a young man with von Willebrand disease (vWD) type 2A, in whom repeated administration of a concentrate containing von Willebrand factor (vWF) and coagulation factor VIII (FVIII) led to successful healing without neurological deficit.
News Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?
Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies associated with nephrolithiasis suggest a possible beneficial effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), a significant group of modern antidiabetics. Below we summarize findings from a study that explored this potential in empagliflozin using conducted phase I–IV studies, including EMPA-REG OUTCOME.
News How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?
Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2 diabetes mellitus (DM2), examining the cardiovascular risk impact when treated with empagliflozin, liraglutide, or sitagliptin. Currently, there is limited evidence comparing the effectiveness of various glucose-lowering agents intended for second-line treatment in DM2 patients undergoing routine care, who have a broad spectrum of cardiorenal risks.
News Reducing Cardiovascular Risk in Diabetics Through Hypertension Treatment
The presence of hypertension in patients with diabetes worsens overall cardiovascular (CV) prognosis and increases the prevalence of chronic renal failure. Adequate treatment of hypertension can significantly influence the development and severity of these complications. What target blood pressure (BP) values should we aim for in diabetics, which antihypertensive therapy to choose, and why not forget about 24-hour BP monitoring?
News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy
William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.
News Current Expert Consensus on Prophylaxis of Individuals with Mild and Moderate Hemophilia A: These Patients Also Deserve Better Care
What is the importance of prophylaxis in 'non-severe' hemophilia A? Italian doctors have attempted to answer this question in their recent expert consensus.
News What Did 3 Years of Data from the Czech National COPD Database Reveal?
In December of last year, the Czech multicenter research database on COPD was completed. This was an extensive 5-year project in which researchers included 784 patients with significant chronic obstructive pulmonary disease (FEV1 ≤ 60%) from 14 centers. This represents approximately 1% of the total number of patients with this diagnosis in the Czech Republic, making the study sample fairly representative for obtaining data on treatment in Czech real practice. Three-year data are currently available. What have they shown so far? This was summarized during this year's Hradec Pulmonology Days by Dr. Jaromír Zatloukal, Ph.D., from the Clinic of Pulmonary Diseases and TB at the Faculty of Medicine, Palacký University and University Hospital Olomouc.
News Pain Management in Patients After Hip and Knee Arthroplasty – Data from Clinical Practice
Inadequate analgesia after hip and knee arthroplasty can result in delayed postoperative recovery accompanied by chronic pain. The retrospective study presented below compared the efficacy of analgesia via continuous epidural infusion of ropivacaine, patient-controlled IV analgesia with the so-called Würzburg drip, and piritramide.
News Hodgkin Lymphoma in a Summary of News from Post-ASH 2021
Dr. Anna Suredová from the Clinical Hematology Department of the Catalonian Oncology Institute in Barcelona, newly elected president of the European Society for Bone Marrow Transplantation (EBMT), also remotely participated in this year's Prague Hematology Days (PHD 2022). In her lecture, she presented an overview of highlights from 4 clinical studies regarding Hodgkin lymphoma (HL) presented during the Post-ASH 2021 meeting.
News IPFchecker Project Helps Detect Patients with Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a serious progressive disease of the lung tissue of unclear etiology. Highly effective antifibrotic therapy is used in treatment, which can significantly prolong the lives of patients. However, timely detection of the disease is necessary for treatment success. For this purpose, the IPFchecker web application has been created, which helps radiologists and pulmonologists with more accurate diagnosis and timely detection of the disease.